Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biologyÓscar M. Pello, Massimo Locati, Maria De Pizzol et al.|Blood|2011Cited by 382
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Lili Du et al.|Cancer Cell|2021Cited by 330
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapyKsenya Shchors, Gérard I. Evan, Anders I. Persson et al.|Proceedings of the National Academy of Sciences|2013Cited by 47
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Claudine Isaacs et al.|npj Breast Cancer|2021Cited by 29